灰指甲治疗市场规模、份额、增长分析，按治疗类型、适应症、年龄组、性别、分销渠道、地区 - 行业预测，2024-2031

2022年全球灰指甲治疗市场规模将为45.2亿美元，从2023年的49.1亿美元成长到2031年的95亿美元，预计在预测期间（2024-2031年）将以复合年增长率成长。年为8.60%）。

由于灰指甲盛行率的不断增加、治疗方案的进步以及人们对该疾病的认识不断增强，灰指甲治疗市场正在显着增长。这个市场包括多种治疗方法，包括外用药物、雷射治疗和口服抗真菌药物。此外，不断增长的医疗保健支出正在改善获得优质治疗方法的机会，从而推动市场扩张。然而，高昂的治疗成本和与某些治疗相关的潜在副作用等挑战正在限制市场动能。财务障碍可能抑制患者接受治疗，特别是雷射治疗和Itraconazole和Terbinafine等口服抗真菌药物等先进治疗方法。此外，对这些药物可能造成肝损伤和胃肠道併发症的担忧也可能导致患者不愿意使用。儘管面临这些挑战，但由于药物开发创新带来的机会，包括奈米技术产品和增强的药物传输系统（例如缓释性製剂和高效的局部治疗），市场有望成长。此类技术创新的出现有望改善患者预后并增加趾甲足癣治疗在医疗保健领域的吸引力。总体而言，不断增长的需求和不断变化的治疗方案相互作用，表明灰指甲治疗市场充满活力的未来。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 次要/一级资讯来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 技术分析
• 价值链分析
• 市场生态系统
• 案例研究分析
• 监管环境
• 创新矩阵
• PESTEL分析
• 主要投资分析
• 关键成功因素
• 竞争程度

灰指甲治疗市场：依治疗类型

• 市场概况
• 药品
  • 口服
  • RX
  • 在商店
  • 局部的
  • RX
  • OTC
• 雷射
  • CO2消融雷射
  • Nd:YAG雷射
  • 双波长近红外线激光
• 动态疗法

灰指甲治疗市场：依适应症划分

• 市场概况
• 远端甲下真菌病
• 白色浅层甲癣
• 近端甲下真菌病
• 念珠菌性甲癣
• 整体性灰指甲

灰指甲治疗市场：依年龄组

• 市场概况
• 0-18岁
• 19-39岁
• 40-64岁
• 65岁以上

灰指甲治疗市场：性别

• 市场概况
• 男性
• 女士

灰指甲治疗市场：按分销管道

• 市场概况
• 向机构投资者出售
  • 医院
  • 皮肤科诊所
• 零售
  • 零售药房
  • 药局
  • 通讯药局/网上销售

灰指甲治疗市场：按地区

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Teva Pharmaceutical Industries Ltd.（Israel）
• Sanofi SA（France）
• Medimetriks Pharmaceuticals, Inc.（US）
• Galderma（Switzerland）
• Johnson & Johnson（US）
• Novartis AG（Switzerland）
• Moberg Pharma AB（Sweden）
• Cardinal Health, Inc.（US）
• Pfizer Inc.（US）
• Almirall, SA（Spain）
• Bayer AG（Germany）
• Viatris Inc.（US）
• GlaxoSmithKline plc（UK）
• Cipla Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Evofem Biosciences, Inc.（US）
• Nabriva Therapeutics plc（Ireland）
• Kaken Pharmaceutical Co., Ltd.（Japan）
• Hikma Pharmaceuticals PLC（UK）
• Dermavant Sciences, Inc.（US）
• Sientra, Inc.（US）
• Zynerba Pharmaceuticals, Inc.（US）

Global Onychomycosis Treatment Market size was valued at USD 4.52 billion in 2022 and is poised to grow from USD 4.91 billion in 2023 to USD 9.5 billion by 2031, growing at a CAGR of 8.60% during the forecast period (2024-2031).

The onychomycosis treatment market is witnessing significant growth driven by the increasing prevalence of nail fungal infections, advancements in treatment options, and heightened awareness about the condition. This market encompasses a variety of treatments, including topical solutions, laser therapies, and oral antifungal medications. Additionally, the rise in healthcare expenditure is enhancing accessibility to superior treatment alternatives, further fueling market expansion. However, challenges such as high treatment costs and potential side effects associated with certain therapies are constraining market momentum. Advanced treatments, particularly laser therapies and oral antifungals like itraconazole and terbinafine, may present financial barriers that deter patient uptake. Moreover, concerns over possible liver damage and gastrointestinal complications associated with these medications can contribute to patient reluctance. Despite these challenges, the market is poised for growth, bolstered by opportunities arising from innovations in drug development, including nanotechnology-driven products and enhanced drug delivery systems such as sustained-release formulations and highly efficacious topical treatments. As these innovations emerge, they hold the promise of improving patient outcomes and increasing the attractiveness of onychomycosis treatments in the healthcare landscape. Overall, the interplay of escalating demand and evolving therapeutic options suggests a dynamic future for the onychomycosis treatment market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Onychomycosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Onychomycosis Treatment Market Segmental Analysis

Global Onychomycosis Treatment Market is segmented by Treatment Type, Disease Indication, Age Group, Gender, Distribution Channel, and region. Based on Treatment Type, the market is segmented into Drugs, Lasers, and Photodynamic Therapy. Based on Disease Indication, the market is segmented into Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Candidal Onychomycosis, and Total Dystrophic Onychomycosis. Based on Age Group, the market is segmented into 0 to 18 Years, 19 to 39 Years, 40 to 64 Years, and 65 Years & Above. Based on Gender, the market is segmented into Male, and Female. Based on Distribution Channel, the market is segmented into Institutional Sales, and Retail Sales. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Onychomycosis Treatment Market

The Global Onychomycosis Treatment market is significantly driven by the increasing prevalence of fungal nail infections, largely attributed to an aging population, rising diabetes rates, and a higher incidence of immunocompromising conditions. As individuals age and comorbidities rise, the susceptibility to onychomycosis escalates, demanding effective treatment options. Additionally, heightened awareness among patients about fungal infections, coupled with improved diagnostic techniques and advanced treatment options being recognized by healthcare professionals, is leading to more accurate diagnoses and subsequent treatments. This confluence of factors not only curtails the stigma associated with fungal infections but also propels market growth as demand for effective therapies surges.

Restraints in the Global Onychomycosis Treatment Market

One prominent market restraint for the Global Onychomycosis Treatment market is the variability in treatment efficacy across diverse patient populations and infection profiles. Many available therapies may not deliver consistent results for all individuals, leading to a significant rate of recurrence, which can diminish patient trust and compliance. Furthermore, treatment effectiveness often hinges on the specific type and severity of the fungal infection, underscoring the imperative for ongoing research and development. This necessity for tailored solutions can hinder market growth, as healthcare providers grapple with the challenge of offering universally effective and reliable treatment options for onychomycosis.

Market Trends of the Global Onychomycosis Treatment Market

The global onychomycosis treatment market is witnessing a significant trend towards the adoption of advanced laser therapies, particularly Carbon Dioxide (CO2) and Blue Light lasers. CO2 lasers dominate this segment due to their ability to penetrate deeper into the nail bed, effectively targeting and eradicating stubborn fungal infections. Meanwhile, Blue Light therapies are gaining traction for treating mild cases or as adjunctive treatments, enhancing overall efficacy. With both modalities delivering heat energy to eliminate pathogens, the trend indicates a shift towards non-invasive, effective solutions, appealing to consumers seeking quick recovery with minimal side effects, thereby driving market growth and innovation.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case study Analysis
• Regulatory Landscape
• Innovation Matrix
• PESTEL Analysis
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Onychomycosis Treatment Market by Treatment Type

• Market Overview
• Drugs
  • Oral
  • RX
  • OTC
  • Tropical
  • RX
  • OTC
• Lasers
  • C02 Ablative Lasers
  • Nd: YAG Lasers
  • Dual-wavelength near-infrared Lasers
• Photodynamic Therapy

Onychomycosis Treatment Market by Disease Indication

• Market Overview
• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• Candidal Onychomycosis
• Total Dystrophic Onychomycosis

Onychomycosis Treatment Market by Age Group

• Market Overview
• 0 to 18 Years
• 19 to 39 Years
• 40 to 64 Years
• 65 Years & Above

Onychomycosis Treatment Market by Gender

• Market Overview
• Male
• Female

Onychomycosis Treatment Market by Distribution Channel

• Market Overview
• Institutional Sales
  • Hospitals
  • Dermatology Clinics
• Retail Sales
  • Retail Pharmacies
  • Drug Stores
  • Mail Order Pharmacies & Online Sales

Onychomycosis Treatment Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medimetriks Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galderma (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moberg Pharma AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almirall, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evofem Biosciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nabriva Therapeutics plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kaken Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dermavant Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sientra, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zynerba Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments